Covaxin
-
BHU study: Over 30 per cent of Covaxin recipients report adverse events
India | May 16, 2024, 11:41 PM ISTThe one-year follow-up study, involving 926 participants, highlighted the long-term safety of the BBV152 vaccine, with serious adverse events like stroke and Guillain-Barre syndrome reported in one percent of recipients.
-
Centre rejects media reports claiming approval for Covaxin rushed due to political pressure
India | Nov 17, 2022, 02:46 PM ISTThe government said the scientific approach and prescribed norms adhered to in approving Covid-19 vaccines for Emergency Use Authorization.
-
COVID: 50 million Covaxin doses set to expire due to poor off take
India | Nov 06, 2022, 01:41 PM ISTCovaxin news: “Covaxin doses in vials are set to expire during early 2023, resulting in losses for the company,” said sources.
-
Japan has approved Covaxin booster dose for travellers: Bharat Biotech
India | Aug 05, 2022, 10:56 PM ISTIn April this year, the Japanese government announced including Covaxin in its list of recognized vaccines to further facilitate travel from India.
-
Covaxin safe, well-tolerated in 2-18 years age-group: Bharat Biotech
India | Jun 17, 2022, 12:25 PM ISTA press release from the vaccine maker said the study has been accepted and published in Lancet Infectious diseases, peer-reviewed high impact factor journal.
-
Covaxin booster dose enhances vaccine effectiveness against Delta, Omicron variants, says ICMR study
India | Jun 15, 2022, 01:46 PM ISTThe findings of the study have been published on Tuesday on bioRxiv, a pre-print server and have not been peer-reviewed.
-
Germany recognises Bharat Biotech's Covaxin for travel from June 1
India | May 26, 2022, 12:07 PM ISTThe DCGI in April also granted an emergency use authorisation (EUA) to Covaxin for the age group of 6-12 years.
-
As Covid cases rise, govt plans to cut waiting period for booster shots to 6 months
India | Apr 28, 2022, 10:26 AM ISTAt present, the gap between the second Covid jab and the precaution dose is nine months.
-
COVID vaccination: DCGI asks Bharat Biotech to provide more data on Covaxin for below 12-year-olds
India | Apr 22, 2022, 02:09 PM ISTThis development comes after the Subject Expert Committee discussed recommendations for the restricted emergency of Covaxin in children aged between 2-12 years.
-
Bharat Biotech to soon rectify issues raised by WHO on Covaxin, say sources
India | Apr 05, 2022, 06:58 AM ISTRecently, in a statement on WHO's suspension of Covaxin, Bharat Biotech said, "For the millions who have received Covaxin, the vaccine certificates issued still stand valid as there is no impact on efficacy and safety of the vaccine."
-
Bharat Biotech says upgrading Covaxin facilities as WHO suspends vaccine supplies
India | Apr 04, 2022, 10:10 AM ISTEarlier on Sunday, Bharat Biotech had said it had nothing else to add to an earlier statement where it said it is working on further improvements and upgrades to ensure that the production of Covaxin continues to meet ever increasing global regulatory requirements.
-
No impact on efficacy and safety of Covaxin: Bharat Biotech after WHO suspension
India | Apr 03, 2022, 09:48 AM ISTThe vaccine manufacturer has further said that the company is slowing down the production of Covaxin for facility optimization.
-
Bharat Biotech says slowing down Covaxin production for facility optimisation
India | Apr 01, 2022, 11:20 PM ISTThe company said after the recent WHO post Emergency Use Listing (EUL) inspection, it is working on further improvements and upgrades to ensure that the production of Covaxin continues to meet ever increasing global regulatory requirements.
-
Covaxin to be evaluated as COVID-19 vaccine candidate in US, says Bharat Biotech
India | Feb 19, 2022, 09:11 PM ISTCovaxin has already been granted Emergency Use Listing (EUL) in 13 countries.
-
Bharat Biotech gets approval for intranasal Covid-19 booster dose trials
India | Jan 28, 2022, 03:56 PM ISTAn intranasal vaccine as a booster dose if becomes a reality would be easier to administer in mass vaccination campaigns and has the potential to prevent transmission.
-
Covishield, Covaxin get regular market approval for use in adult population
India | Dec 15, 2022, 03:27 PM ISTThe DCGI approval came after the Subject Expert Committee (SEC) on COVID-19 recommended granting regular market approval to Covishield and Covaxin.
-
Each dose of Covishield, Covaxin likely to be capped at Rs 275 upon market approval
India | Dec 15, 2022, 03:30 PM ISTCovaxin and Covishield were granted Emergency Use Authorisation (EUA) on January 3 last year.
-
MVA wins Maharashtra Nagar Panchayat polls but BJP emerges single largest party
India | Jan 19, 2022, 11:22 PM ISTThe BJP emerged as the single largest party bagging 384 seats against the MVA tally of 944 comprising Nationalist Congress Party's 344, Congress' 316 and Shiv Sena's 284 seats.
-
Covishield, Covaxin get govt expert panel's recommendation for regular market approval
India | Jan 20, 2022, 09:31 AM ISTPharma companies Serum Institute of India (SII) and Bharat Biotech had submitted applications to the Drugs Controller General of India (DCGI) seeking regular market authorisation for their respective COVID-19 vaccines Covishield and Covaxin.
-
Covaxin now universal vaccine for adults, children: Bharat Biotech
India | Jan 14, 2022, 07:26 AM ISTEarlier, Hyderabad-based Hyderabad-based vaccine manufacturer had claimed that its COVID vaccine Covaxin can neutralise both Delta and Omicron variants of coronavirus.